J&J’s Janssen Seeks European Expansion of Tremfya for Psoriatic Arthritis

Johnson & Johnson’s (JNJ) Janssen Pharmaceutical Cos. unit on Wednesday said it filed for European Medicines Agency expanded approval of Tremfya for adults with active psoriatic arthritis.
The drug maker said it estimated that up to a third of the 14 million Europeans suffering from psoriasis will also develop psoriatic arthritis, a chronic inflammatory disease characterized by joint inflammation and the skin lesions associated with psoriasis.
Janssen received European Union approval in November 2017 for Tremfya in adults with moderate to severe plaque psoriasis.

https://www.marketscreener.com/JOHNSON-JOHNSON-4832/news/Johnson-Johnson-J-J-s-Janssen-Seeks-European-Expansion-of-Tremfya-for-Psoriatic-Arthritis-29439836/